[go: up one dir, main page]

KR900013949A - 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 - Google Patents

정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도 Download PDF

Info

Publication number
KR900013949A
KR900013949A KR1019900002912A KR900002912A KR900013949A KR 900013949 A KR900013949 A KR 900013949A KR 1019900002912 A KR1019900002912 A KR 1019900002912A KR 900002912 A KR900002912 A KR 900002912A KR 900013949 A KR900013949 A KR 900013949A
Authority
KR
South Korea
Prior art keywords
compound
tetrahydro
cis
naphthalene amine
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900002912A
Other languages
English (en)
Other versions
KR920005810B1 (ko
Inventor
케니쓰 코에 빌리
Original Assignee
알렌 제이.스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900013949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알렌 제이.스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이.스피겔
Publication of KR900013949A publication Critical patent/KR900013949A/ko
Application granted granted Critical
Publication of KR920005810B1 publication Critical patent/KR920005810B1/ko
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 정신병치료, 소염 또는 면역억제 효과량의 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용되는 산부가 염을 정신병치료, 소염 또는 면역억제를 필요로 하는 포유동물에게 투여함을 포함하는, 상기 포유동물에서 정신병치료, 소염 또는 면역억제 효과를 얻는 방법 :
    상기식에서, R1은 수소 및 C1내지 C3알킬로 구성된 그룹중에서 선택되고, R2는 C1내지 C3알킬이고, Z는(여기에서, X와 Y는 각각 독립적으로 수소, 플루오로, 크로로, 브로모, 트리플루오로메틸, C1내지 C3의 알콕시 및 시아노로 구성된 그룹중에서 선택되고, X와 Y중 적어도 하나는 수소가 아니다)이고, W는 수소, 플루오로, 클로로, 브로모, 트리플루오로메틸 및 C1내지 C3의 알콕시로 구성된 그룹중에서 선택된다.
  2. 제1항에 있어서, 상기 화합물이 시스 또는 트란스 이성체인 방법.
  3. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  4. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-4-(4-클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  5. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N-메틸-(3-트리플루오로메틸, 4-클로로-페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  6. 제1항에 있어서, 상기 화합물이 트란스-(1S) (1R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  7. 제1항에 있어서, 상기 화합물이 트란스-(1S) (4S)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  8. 제1항에 있어서, 상기 화합물이 시스-(1S) (4R)-N-메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  9. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-아미노-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  10. 제1항에 있어서, 상기 화합물이 시스-(1S) (4S)-N,N-디메틸-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌 아민인 방법.
  11. 정신병치료, 소염 또는 면역억제 효과량의 제1항의 화합물과 약학적으로 허용되는 담체를 함체 포함하는 정신병 및 염증치료와 면역억제 유도를 위한 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900002912A 1989-03-07 1990-03-06 정신병 치료제 Expired KR920005810B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US320,014 1989-03-07
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US320.014 1989-03-07

Publications (2)

Publication Number Publication Date
KR900013949A true KR900013949A (ko) 1990-10-22
KR920005810B1 KR920005810B1 (ko) 1992-07-20

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900002912A Expired KR920005810B1 (ko) 1989-03-07 1990-03-06 정신병 치료제

Country Status (17)

Country Link
US (2) US4981870A (ko)
EP (1) EP0386997B1 (ko)
JP (2) JPH0714870B2 (ko)
KR (1) KR920005810B1 (ko)
AT (1) ATE150299T1 (ko)
AU (1) AU610036B2 (ko)
CA (1) CA2011428C (ko)
DE (1) DE69030212T2 (ko)
DK (1) DK0386997T3 (ko)
HU (1) HU221624B1 (ko)
IE (1) IE81047B1 (ko)
IL (1) IL93576A (ko)
MY (1) MY106272A (ko)
NZ (1) NZ232800A (ko)
PH (1) PH26542A (ko)
PT (1) PT93351B (ko)
ZA (1) ZA901743B (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
CA2166100A1 (en) * 1993-06-23 1995-01-05 Richard A. Glennon Sigma receptor ligands and the use thereof
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
SK180499A3 (en) 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
US20040087661A1 (en) * 2002-09-16 2004-05-06 Sepracor, Inc. Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
BRPI0314377B8 (pt) 2002-09-16 2021-05-25 Sepracor Inc composto, composição farmacêutica, tablete ou cápsula, uso de uma quantidade terapeuticamente eficaz, e, processo para preparar um composto
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2004312530A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
WO2007006003A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
ES2566479T3 (es) * 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
KR101294014B1 (ko) * 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2816024B8 (en) * 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
JP2009538925A (ja) * 2006-05-31 2009-11-12 セプラコール， インク． ｔｒａｎｓ４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドを用いる疼痛性障害の治療
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
ZA200904686B (en) * 2007-01-18 2010-09-29 Sepracor Inc Inhibitiors of D-amino acid oxidase
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
CN101686672A (zh) 2007-05-31 2010-03-31 塞普拉柯公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP3142999A4 (en) * 2014-05-13 2017-12-27 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of adhd
JP2017515849A (ja) * 2014-05-13 2017-06-15 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Ａｄｈｄを治療するためのダソトラリン用量および治療方法
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
US10159648B2 (en) 2015-05-22 2018-12-25 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
MY106272A (en) 1995-04-29
JP3020808B2 (ja) 2000-03-15
IL93576A0 (en) 1990-11-29
IE900798L (en) 1990-09-07
EP0386997B1 (en) 1997-03-19
DK0386997T3 (da) 1997-04-14
HUT59000A (en) 1992-04-28
CA2011428A1 (en) 1990-09-07
JPH0714870B2 (ja) 1995-02-22
US4981870A (en) 1991-01-01
EP0386997A2 (en) 1990-09-12
DE69030212D1 (de) 1997-04-24
HU221624B1 (hu) 2002-12-28
US5061728A (en) 1991-10-29
PT93351B (pt) 1996-03-29
NZ232800A (en) 1997-07-27
AU610036B2 (en) 1991-05-09
EP0386997A3 (en) 1992-04-29
ZA901743B (en) 1991-10-30
CA2011428C (en) 1994-11-08
ATE150299T1 (de) 1997-04-15
DE69030212T2 (de) 1997-06-26
HU901325D0 (en) 1990-05-28
AU5079690A (en) 1990-09-20
JPH07173056A (ja) 1995-07-11
JPH02300121A (ja) 1990-12-12
PH26542A (en) 1992-08-19
PT93351A (pt) 1990-11-07
IE81047B1 (en) 1999-12-01
IL93576A (en) 1995-12-08
KR920005810B1 (ko) 1992-07-20

Similar Documents

Publication Publication Date Title
KR900013949A (ko) 정신병 및 염증치료와 면역억제제로의 4-페닐-1,2,3,4-테트라하이드로-1-나프탈렌 아민 유도체의 용도
KR970059163A (ko) 할로겐기가 치환된 2-페닐-1, 2-에탄디올 카바메이트 화합물
KR910004572A (ko) 아자비시클로 퀴놀론 카르복실산
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
IL61374A0 (en) Derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions containing them
KR950031074A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR890003369A (ko) 약제학적 제제
KR930019655A (ko) 종양치료 조성물 및 치료방법
KR940005270A (ko) 뼈 손실 예방에 유용한 벤조티오펜
CO4920242A1 (es) Compuestos inhibidores de metalopreoteasas 1,4-heterocicli- cos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
MA28328A1 (fr) Combinaisons d'agents actifs synergiques fongicides
AR018732A1 (es) Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene.
ES2155093T3 (es) Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).
MX9700429A (es) El uso de compuestos de tiazol y tiadiazol.
AR044337A1 (es) Procedimiento para potenciar la cognicion usando ziprasidona
PE20081781A1 (es) Agonistas de adrenoreceptores alfa2c funcionalmente selectivos
ATE209177T1 (de) Von einem aromatischen oder heteroaromatischen radikal substituierte biphenylderivate und diese enthaltende pharmaceutische und kosmetische compositionen
RU2004110041A (ru) Фармацевтическая композиция, содержащая габапентин или его аналог и альфа-аминоамид, и ее применение в качестве анальгетика
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR930005972A (ko) N-알킬-3-페닐-3-(2-알킬티오페녹시)프로필아민
AR062112A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
RU98106625A (ru) Производные колхицина и тиоколхицина, обладающие противовоспалительной и миорелаксирующей активностями
AR032653A1 (es) Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
NZ263202A (en) Topical pharmaceutical compositions containing urocanic acid-type agents

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

FPAY Annual fee payment

Payment date: 20040701

Year of fee payment: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20050721

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20050721

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000